Swan Capital’s Fulgent Genetics FLGT Stock Holding History

Swan Capital’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-66	Closed	-$1.73K	–	580
2025 Q4	$1.73K	Buy	+66	New	+$1.71K	﹤0.01%	344

Other funds holding FLGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Swan Capital's FLGT Position: Q1 2026 in Review

Swan Capital sold out of Fulgent Genetics (FLGT) in Q1 2026, closing a stake of 66 shares — an estimated $1.73K sold.

Swan Capital first reported a position in FLGT in Q4 2025 and held it in 1 quarter. The position peaked at $1.73K in Q4 2025. 157 funds tracked by Wall St. Rank hold FLGT as of Q1 2026.

Swan Capital reported no remaining Fulgent Genetics position as of Q1 2026 after selling out during the quarter.
Swan Capital sold 66 Fulgent Genetics shares in Q1 2026, an estimated $1.73K.
Swan Capital first reported a position in Fulgent Genetics in Q4 2025 and held it in 1 quarter.
Swan Capital's Fulgent Genetics position peaked at $1.73K in Q4 2025.
157 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2026.

Based on Swan Capital's 13F filing for Q1 2026, filed 14 May 2026.